MDACC Study No:2008-0204 ( NCT No: NCT00901927)
Title:A Phase II Study of Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients with Untreated High Risk Follicular Lymphoma
Principal Investigator:Nathan Fowler
Treatment Agent:Bendamustine HCl; Mitoxantrone; Rituximab
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of
bendamustine hydrochloride, mitoxantrone, and rituximab can help to control
follicular lymphoma.

The safety of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Bendamustine HCl
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:n/a
Supported By:Cephalon Oncology
Return Visit:Screening, Cycles 1-6, Days 1,2,8,15,22. End of Treatment, Follow-up and End of
Home Care:n/a

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nathan Fowler
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults